Immunocytochemical studies of the rat adenohypophysis identified a cell population that exhibits immunoreactivity for type-2 vesicular glutamate transporter (VGLUT2), a marker for glutamatergic neuronal phenotype. The in situ hybridization detection of VGLUT2 mRNA expression in adenohypophysial cells verified that VGLUT2 immunoreactivity is due to local synthesis of authentic VGLUT2. Dual-immunofluorescent studies of the hypophyses from male rats showed the presence of VGLUT2 in high percentages of LH (93.3 ؎ selectively accumulate l-glutamate into synaptic vesicles; these proteins are thus also viewed as histochemical markers for excitatory neurons that use l-glutamate for synaptic communication. The three molecular forms of VGLUT are expressed by distinct classes of glutamatergic neurons in the central nervous system (1-10). Recent studies have established that several hypothalamic regions involved in neuroendocrine regulation synthesize the mRNA and protein for the VGLUT2 isoform (8, 9). Hypophysiotropic neurosecretory systems shown to possess VGLUT2 mRNA and protein include GnRH neurons of the preoptic area (11), TRH (12), and CRH (12) neurons of the paraventricular nucleus and somatostatin (13) neurons of the paraventricular and anterior periventricular nuclei. The identification of VGLUT2 immunoreactivity in neurosecretory terminals in the external zone of the median eminence indicates that these systems may corelease l-glutamate with the peptide neurohormones (11). It is currently unclear whether the putative secretory glutamate acts locally on cellular elements of the median eminence, or else is carried away by the portal circulation to regulate ultimately adenohypophysial cells bearing glutamate receptors (14, 15) . In addition to the glutamatergic characteristics of various parvicellular neuroendocrine systems, recent studies have also provided evidence for the VGLUT2 phenotype of magnocellular neurosecretory oxytocin and vasopressin neurons (16, 17) .
V ESICULAR GLUTAMATE transporters (VGLUT1-3)
selectively accumulate l-glutamate into synaptic vesicles; these proteins are thus also viewed as histochemical markers for excitatory neurons that use l-glutamate for synaptic communication. The three molecular forms of VGLUT are expressed by distinct classes of glutamatergic neurons in the central nervous system (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Recent studies have established that several hypothalamic regions involved in neuroendocrine regulation synthesize the mRNA and protein for the VGLUT2 isoform (8, 9) . Hypophysiotropic neurosecretory systems shown to possess VGLUT2 mRNA and protein include GnRH neurons of the preoptic area (11) , TRH (12) , and CRH (12) neurons of the paraventricular nucleus and somatostatin (13) neurons of the paraventricular and anterior periventricular nuclei. The identification of VGLUT2 immunoreactivity in neurosecretory terminals in the external zone of the median eminence indicates that these systems may corelease l-glutamate with the peptide neurohormones (11) . It is currently unclear whether the putative secretory glutamate acts locally on cellular elements of the median eminence, or else is carried away by the portal circulation to regulate ultimately adenohypophysial cells bearing glutamate receptors (14, 15) . In addition to the glutamatergic characteristics of various parvicellular neuroendocrine systems, recent studies have also provided evidence for the VGLUT2 phenotype of magnocellular neurosecretory oxytocin and vasopressin neurons (16, 17) .
Beyond the putative cosecretion of glutamate from neuroendocrine axon terminals, there is emerging evidence that the VGLUT isoforms can also occur in nonneural endocrine tissues (18) . The pineal gland contains both the VGLUT1 and the VGLUT2 isoforms (19, 20) and various endocrine cells of the gastrointestinal tract, including ␣ and F cells of the pancreatic Langerhans islets and intestinal L cells (20, 21) , also synthesize VGLUT2. In the present studies, we used immunocytochemistry and in situ hybridization (ISH) to investigate the putative synthesis of VGLUT2 in peptide hormonesecreting cells of the adenohypophysis. The functional phenotype of VGLUT2-immunoreactive adenohypophysial cells was addressed by dual-immunofluorescent histochemistry followed by confocal laser microscopic analysis. Based on preliminary results of these experiments which identified VGLUT2 immunoreactivity in gonadotrope and thyrotrope cells, the issues of whether and how the estrogen status and the thyroid hormone status regulate adenohypophysial VGLUT2 mRNA expression, have been addressed. Quantitative ISH studies were carried out to compare VGLUT2 hybridization signals in adenohypophysial sections from ovariectomized vs. ovariectomized and estrogen-treated female rats and from hypothyroid vs. euthyroid vs. hyperthyroid male rats. Subsequent dual-immunofluorescent studies also analyzed putative alterations of VGLUT2 immunoreactivity within adenohypophysial cells of these endocrine models.
Materials and Methods

Tissue preparations
Adult male [n ϭ 33; 200 -225 g body weight (bw)] and female (n ϭ 17; 200 -225 g bw) Wistar rats were purchased from the local breeding colony of the Medical Gene Technology Unit of the Institute of Experimental Medicine. The animals were maintained under a 12-h d/12-h night schedule (lights on 0700 -1900 h), in a temperature (22 Ϯ 2 C) and humidity (60 Ϯ 10%) controlled environment with free access to laboratory rat food (Sniff Spezialdiaeten GmbH, Soest, Germany) and tap water. All experiments were carried out in accordance with the Council Directive of 24 November 1986 of the European Communities (86/609/ EEC) and were reviewed and approved by the Animal Welfare Committee of the Institute of Experimental Medicine (47/003/2005).
Tissue preparation for light and confocal microscopic studies
To collect pituitaries for immunocytochemical experiments, rats were deeply anesthetized with pentobarbital (35 mg/kg bw, ip) and perfused transcardially, first with 20 ml of 0.1 m PBS (pH 7.4), and then with 150 ml fixative solution containing 4% paraformaldehyde (Sigma Chemical Co., St. Louis, MO) in PBS. To provide a firm support for floating hypophysial sections, the glands were immersed in fresh egg-yolk and exposed to formalin fumes for 48 h, as recommended for the processing of soft histological specimens by others (22) . The hardened blocks were trimmed, soaked in 20% sucrose for 72 h, and snap-frozen on powdered dry ice. Then, 20-m-thick free-floating sections were prepared with a Leica SM 2000R freezing microtome (Leica Microsystems, Nussloch Gmbh, Nussloch, Germany). Endogenous peroxidase activity was eliminated, and sections were permeabilized by a 30-min incubation in 1% H 2 O 2 and 0.4% Triton X-100 in PBS. Then the tissues were treated with 2% normal horse serum in TBS (0.1 m Tris-HCl with 0.9% NaCl; pH 7.8) to prevent nonspecific binding of the antibodies.
Tissue preparation for ISH studies
Four rats used for the ISH detection of adenohypophysial VGLUT2 mRNA were briefly anesthetized in a CO 2 atmosphere and decapitated. The hypophysis of each animal was removed, placed in a metal mold containing Jung tissue freezing medium (Leica Microsystems, Nussloch Gmbh; diluted 1:1 with 0.9% sodium chloride solution) and aligned. The blocks were snap-frozen on powdered dry ice. Sixteen-micrometer-thick coronal sections were cut from the frozen pituitary blocks with a Leica CM 3050 S cryostat (Leica Microsystems), thaw-mounted on gelatincoated microscope slides, and air-dried.
Experiment 1: demonstration of VGLUT2 immunoreactive adenohypophysial cells using peroxidase immunocytochemistry
Paraformaldehyde-fixed pituitary sections of five male rats were incubated in either mouse primary VGLUT2 antibodies (MAB 5504, 1:500; Chemicon, Temecula, CA) or rabbit primary VGLUT2 antibodies (135103, 1:2000; SYnaptic SYstems, Gö ttingen, Germany) for 5 d on a shaking platform at 4 C. This was followed by sequential treatments with species-specific biotinylated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA; 1:1000) for 2 h (room temperature) and ABC Elite working solution (1:1000; Vector Laboratories, Burlingame, CA) for 1 h (room temperature). The peroxidase signals were visualized with 3,3Ј-diaminobenzidine tetrahydrochloride (DAB) in the peroxidase developer, in either the presence or the absence of nickel ions. After chromogen deposition, the immunostained pituitary sections were mounted on microscope slides from Elvanol, air-dried, dehydrated with 95% (5 min) followed by 100% (2 ϫ 5 min) ethanol, cleared with xylene (2 ϫ 5 min), coverslipped with DPX mounting medium (Fluka Chemie, Buchs, Switzerland), and studied with an Axiophot microscope (Zeiss, Gö ttingen, Germany) equipped with an RT Spot digital camera (Diagnostic Instrument, Sterling Heights, MI).
Experiment 2: dual-immunofluorescent detection of VGLUT2 immunoreactive adenohypophysial cells in positive control studies
Positive control experiments to confirm the authenticity of VGLUT2 immunoreactivity applied the mixture of the two different VGLUT2 antibodies to the same tissue sections for dual-immunofluorescent labeling, similarly to strategies used recently (11, 12) . The mouse and rabbit primary antibodies (used at 1:300 and 1:1000 dilutions, respectively) were reacted for 12 h with a cocktail of Cy3-conjugated antimouse IgG and FITC-conjugated antirabbit IgG (Jackson ImmunoResearch Laboratories; 1:100 each). The immunofluorescent specimens were mounted on glass slides from 0.05 m Tris/HCl solution (pH 7.8), dried, and coverslipped with Vectashield mounting medium (Vector Laboratories). Confocal microscopic analysis of the specimens was carried out as detailed under experiment 4.
Experiment 3: demonstration of VGLUT2 mRNA expression in adenohypophysial cells using ISH
To provide further confirmation to the concept that VGLUT2 immunoreactivity in adenohypophysial cells is due to local synthesis of the authentic VGLUT2 molecules, slide-mounted hypophysial sections from four male rats were processed for the ISH detection of VGLUT2 mRNA with a sensitized radioisotopic ISH procedure (23) . The preparation and use of a 879-base 35 S-labeled cRNA hybridization probe to bases 522-1400 of VGLUT2 mRNA (GenBank accession no. NM 053427) have been detailed in recent publications from our laboratory (11) (12) (13) . After posthybridization treatments which included the RNase A digestion (50 g/ml, 30 min at 37 C) of probe excess (24) , the sections were dehydrated, air-dried, and coated with NTB-3 autoradiographic emulsion (Kodak, Rochester, NY), diluted 1:1 with MQ water. After 2 wk of exposure, the slide autoradiographs were developed with D19 developer (Kodak; diluted 1:1 with MQ water; 2 min), rinsed with MQ water (30 sec), and fixed with Kodak fixer (5 min). Then, the slides were rinsed in several changes of chilled MQ water, counter-stained lightly with toluidine blue, air-dried, transferred briefly into xylene (30 sec) and coverslipped with DPX mounting medium (Fluka Chemie). Negative control experiments included the use of 35 S-labeled sense probes for ISH studies and the omission of primary antibodies for immunocytochemistry. A positive control for ISH labeling specificity (11-13) was to substitute the VGLUT2-879 probe with a distinct probe ("VGLUT2-734", a kind gift from Dr. J. P. Herman, University of Cincinnati Medical Center, Cincinnati, OH) against a nonoverlapping segment of VGLUT2 mRNA (8) .
Experiment 4: immunofluorescent experiments to determine the functional phenotype of VGLUT2 expressing adenohypophysial cells
To determine the functional phenotype of adenohypophysial cells that exhibit VGLUT2 immunoreactivity, a series of dual-immunofluorescent studies was carried out for the simultaneous detection of VGLUT2 and different adenohypophysial hormones. Sections from five male animals were first incubated in the mouse monoclonal VGLUT2 antibodies (1:300, Chemicon) for 72 h and then, in Cy3-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories; 1:100) for 12 h. Subsequently, the sections were incubated in rabbit polyclonal antisera from Accurate (Westbury, NY) against rat GH (1:1000), ACTH (1:1000), LH (1:1000), FSH (1:1000), TSH (1:1000), or rat prolactin [S13 anti-prolactin (PRL); 1:1000; kind gift from Dr. Gyö rgy Nagy, Semmelweis University, Budapest Hungary] (25, 26) . The incubation in the primary antibodies was followed by FITC-conjugated antirabbit secondary antibodies (Jackson ImmunoResearch Laboratories; 1:100) for 12 h. The dual-immunofluorescent specimens were mounted on glass slides from 0.05 m Tris/HCl (pH 7.8) solution, dried, and coverslipped with Vectashield medium (Vector Laboratories). Cells that were immunoreactive for VGLUT2 thus appeared in red, whereas peptide-immunoreactive cells appeared in green using the following epifluorescent filter sets of the Zeiss Axiophot epifluorescent microscope: for Cy3, excitation of 540 -590 nm, bandpass of 595 nm, and emission of 600 -660 nm; for FITC, excitation of 460 -500 nm, bandpass of 505 nm, and emission of 510 -560 nm. Dual-immunofluorescent specimens were analyzed further with a Radiance 2100 confocal microscope (Bio-Rad Laboratories, Hemel Hempstead, UK) using laser excitation lines 488 nm for FITC and 543 nm for Cy3 and dichroic/emission filters 560 nm/500 -530 nm for FITC and 560 -610 nm for Cy3. To eliminate emission cross-talk, single optical slices (Ͻ0.7 m) were collected in " strobing" mode so that only one excitation laser and the corresponding emission detector were active during a line scan (13) . The digital images were processed with the Adobe PhotoShop 7.0 software at 300 dpi resolution.
To determine the percent ratios of double-labeled LH, FSH, and TSH cells in each set of dual-labeling experiment, individual hormone-immunoreactive cells were analyzed at high magnification for the presence/absence of the VGLUT2 immunofluorescent signal, by switching between the epifluorescent filter sets for Cy3 and FITC. The percent ratios of VGLUT2 containing PRL, GH, and ACTH cells were analyzed on confocal images. Each quantitative analysis included at least 100 randomly selected adenohypophysial cells from each of five male animals and results were expressed as mean from the five animals Ϯ sem.
Experiment 5: studies on the estrogenic regulation of adenohypophysial VGLUT2 mRNA
Nine female rats were bilaterally ovariectomized under pentobarbital anesthesia (35 mg/kg bw, ip). On postovariectomy d 11, five of these gonadectomized rats [ovariectomized and estradiol-treated (OVX ϩ E2) group] received a single sc injection of 17-␤-estradiol (20 g/kg, bw) in sunflower oil, whereas control rats [n ϭ 4; ovariectomized (OVX) group] were injected with the vehicle. This dose of 17-␤-estradiol was chosen to safely saturate tissue estrogen receptors (27) . Sixteen hours after the injections, the rats were decapitated and the hypophyses were embedded into freezing medium (diluted 1:1 with 0.9% NaCl solution) and frozen on dry ice. Sixteen-micrometer-thick sections were prepared from each pituitary, thaw-mounted, and dried on glass slides and hybridized with the antisense "VGLUT2-879" probe as described under experiment 3. After posthybridization treatments, the sections were exposed to Fujifilm imaging plates for 48 h. The images were scanned with a Fujifilm FLA-3000 phosphorimager system and archived in TIF mode. The files were opened for the analysis with the Image J image analysis software (public domain at http://rsb.info.nih.gov/ij/download/src/). The threshold was set to highlight the entire tissue surface. The adenohypophysis was selected and its mean gray level was determined. Each animal was characterized with the mean of four measurements (from four hypophysial sections). The mean gray levels in the OVX and the OVX ϩ E2 groups were compared with one-way ANOVA.
Experiment 6: studies on the effects of thyroid hormone status on adenohypophysial VGLUT2 mRNA
The issues of whether and how the thyroid hormone status regulates VGLUT2 mRNA expression in the adenohypophysis have been addressed using a similar quantitative ISH strategy to the one described for experiment 5. Methods to generate hypothyroid and hyperthyroid rat models have been detailed elsewhere (28 -30) . In brief, adult male Wistar rats were made hypothyroid by a treatment with 0.02% methimazole in the drinking water for 3 wk. Control euthyroid rats (n ϭ 8) received regular tap water. Hyperthyroid rats (n ϭ 8) received tap water and were injected daily for 10 d with 10 g T 4 (i.p). The animals were decapitated, and their hypophysis was processed for quantitative ISH studies of VGLUT2 mRNA expression as described under experiment 5.
The effect of treatments was analyzed with one-way ANOVA, followed by Newman-Keuls test.
Experiment 7: effects of endocrine status on adenohypophysial VGLUT2 immunoreactivity
Dual-immunofluorescent studies to localize VGLUT2 immunoreactivity within LH, TSH, and other adenohypophysial cell types have been replicated in methimazole-treated hypothyroid (n ϭ 4) vs. euthyroid control (n ϭ 4) male rats and in OVX (n ϭ 4) vs. OVX ϩ E2 (n ϭ 4) female rats. The percent ratios of VGLUT2 immunoreactive LH, TSH, and PRL cells in different animal models were compared by one-way ANOVA to see whether endocrine alterations affect the incidence of these colocalizations.
Results
Experiment 1: demonstration of VGLUT2 immunoreactive adenohypophysial cells using peroxidase immunocytochemistry
The results of immunocytochemical experiments revealed VGLUT2 immunoreactivity in magnocellular axon terminals of the neural lobe (Fig 1A) , corroborating recent findings by our group (16) and others (17) . In addition to this fiber staining in the neurohypophysis, many adenohypophysial cells in the anterior lobe and a few in the intermediate lobe exhibited VGLUT2 immunoreactivity in their cytoplasm (Fig. 1A) . High-power microscopic analysis of the anterior lobe using either the mouse or the rat VGLUT2 antibodies (Fig. 1, B and C) revealed that the labeled elements corresponded to relatively large endocrine cells dispersed throughout the gland (Fig. 1, B and C).
Experiment 2: dual-immunofluorescent detection of VGLUT2 immunoreactive adenohypophysial cells in positive control studies
The combined use of the two different VGLUT2 primary antibodies, followed by appropriate species-specific secondary antibodies which were conjugated with different fluorochroms, resulted in dual-immunofluorescent labeling of immunoreactive adenohypophysial cells, in strong support of labeling specificity for VGLUT2 (Fig. 2, A-C) .
Experiment 3: demonstration of VGLUT2 mRNA expression in adenohypophysial cells using ISH histochemistry
ISH experiments identified well-defined clusters of silver grains in the emulsion autoradiographs after 2 wk of exposure (Fig. 1, D and E) . These ISH results served as further proof of authentic VGLUT2 synthesis by a subset of adenohypophysial cells. Hybridization specificity was confirmed by the similar results obtained with the two distinct antisense VGLUT2 probes and the absence of grain clusters when using sense RNA transcripts for negative control (data not shown).
Experiment 4: immunofluorescent experiments to determine the functional phenotype of VGLUT2 expressing adenohypophysial cells
The analysis of a series of sections dual-labeled for VGLUT2 and one of the hypophysial peptide hormones, established that VGLUT2 immunoreactivity was absent from the vast majority of the corticotrope (Fig. 2D) , somatotrope (Fig. 2E) , and lactotrope (Fig. 2F ) cells, although a few cells of each phenotype (Ͻ8%; see inset in Fig. 2F ) cocontained the VGLUT2 signal. In contrast, the immunocytochemical signal for VGLUT2 tended to be specifically associated with three different phenotypes of glycoprotein-secreting endocrine cells that were immunoreactive to LH, FSH, and TSH (Fig. 2,  G, H, and I) . The quantitative analysis to estimate the ratios of double-labeled cells in male rats identified VGLUT2 immunoreactivity in 93.3 Ϯ 1.3% of LH-, 44.7 Ϯ 3.9% of FSH-, 70.0 Ϯ 5.6% of TSH-, 7.7 Ϯ 4.2% of PRL-, 6.6 Ϯ 1.6% of GH-, and 3.3 Ϯ 0.6% of ACTH-immunoreactive cells (Fig. 3) .
Experiment 5: studies on the estrogenic regulation of adenohypophysial VGLUT2 mRNA
The quantitative densitometric analysis of autoradiographic images captured on a phosphorimager screen established that the adenohypophyses of OVX ϩ E2 female rats contained significantly higher levels of VGLUT2 mRNA (higher mean gray value) than did the anterior lobes of the OVX group [F(1;7) ϭ 9.40; P ϭ 0.0182] (Fig. 4) .
Experiment 6: studies on the effects of thyroid hormone status on adenohypophysial VGLUT2 mRNA
The quantitative analysis of ISH autoradiographs from hypothyroid, euthyroid, and hyperthyroid rats identified a significant effect [F(2;21) ϭ 42.25; P ϭ 0.0001] of thyroid status on adenohypophysial VGLUT2 mRNA levels (mean gray value). There was no difference between VGLUT2 signals in the hyperthyroid and euthyroid groups (P ϭ 0.8089), whereas hypothyroid animals exhibited significantly higher VGLUT2 mRNA expression than did euthyroid (P ϭ 0.0001) and hyperthyroid (P ϭ 0.0001) rats (Fig. 5 ).
Experiment 7: effects of endocrine status on adenohypophysial VGLUT2 immunoreactivity
Nearly all of the LH cells in both the OVX (94.6 Ϯ 2.0%) and the OVX ϩ E2 (96.9 Ϯ 0.7%) groups contained VGLUT2 immunoreactivity (Fig. 5, A-D) . Robust alterations were observed in the morphology of TSH cells in the hypothyroid male rats, corroborating previous findings by others (31) . The activated thyrotropes increased in number as well as in size, and they displayed a decreased immunolabeling for TSH (Fig. 6G) . A significantly lower ratio [(F(1;6) ϭ 44.4; P ϭ 0.0005) by ANOVA] of TSH cells contained the immunofluorescent signal for VGLUT2 in hypothyroid (29.7 Ϯ 5.0%) than in euthyroid control (64.8 Ϯ 0.8%) rats (Fig. 6, E-H) . The analysis of VGLUT2 immunoreactivity in hypothyroid and euthyroid male rats and in OVX and OVX ϩ E2 female rats showed that VGLUT2 was mainly detectable in the same cell types, gonadotropes and thyrotropes, as in intact male rats. The incidence of VGLUT2 colocalization was low in PRL cells of OVX female (6.2 Ϯ 0.5%) and euthyroid male (7.9 Ϯ 2.0%) rats, and it was not altered as a result of estrogen treatment or hypothyroidism, respectively (by ANOVA). 
Discussion
The results of this study provided immunocytochemical and ISH evidence that the authentic VGLUT2 molecule, a marker for the glutamatergic neuronal phenotype, is present in high percentages of gonadotrope and thyrotrope cells and also occurs in small subsets of corticotrope, somatotrope, and lactotrope cells of the rat adenohypophysis. The quantitative comparison of adenohypophysial VGLUT2 mRNA levels in ovariectomized vs. ovariectomized and estrogen-injected female rats revealed the up-regulation of VGLUT2 mRNA expression 16 h after sc. administration of a single dose of 17-␤-estradiol. VGLUT2 levels were also significantly increased in hypothyroid rats after a 3-wk treatment with methimazole in the drinking water, whereas the hyperthyroid state (induced by daily T 4 injections for 10 d) did not influence VGLUT2 mRNA levels.
Before quantal exocytotic release, classical neurotransmitters including l-glutamate are packaged into synaptic vesicles by vesicular neurotransmitter transporters (32) . The brain-specific Na ϩ -dependent inorganic phosphate cotransporter (33) was shown to fulfill the criteria required for the VGLUT, and hence, was renamed VGLUT1 (1, 34) . Intense investigations have subsequently identified the second and third isoforms of VGLUT (VGLUT2 and VGLUT3) (2, 4 -7, 20, 35-37) . In addition to the presynaptic occurrence of the different VGLUT isoforms in excitatory synapses (2-4, 38), several phenotypes of neurosecretory axons in the median eminence were also found to contain the glutamatergic marker VGLUT2 (11-13). As synaptic specializations at this neurosecretion site are rare (39), glutamatergic mechanisms acting in the median eminence apparently differ from the classical glutamatergic synaptic neurotransmission. The secretory glutamate may exert autocrine/paracrine effects on the putative neuronal glutamate receptors of axon terminals. Furthermore, it may also influence neighboring glial elements containing glutamate receptors (40, 41) or endothelial cells.
The present study, to analyze the putative expression of VGLUT2 in peptide hormone secreting cells of the anterior pituitary, was strongly motivated by recent data showing VGLUT2 in peripherial endocrine organs including cells of the pancreatic Langerhans islets (20) , as well as our preliminary observation of VGLUT2-like immunoreactivity in the anterior lobe of the rat pituitary during studies of VGLUT2 immunoreactivity in magnocellular axon terminals in the neurohypophysis (16) . The authenticity of adenohypophysial VGLUT2 immunoreactivity was confirmed using simultaneously two distinct VGLUT2 antibodies for dual-immunofluorescent labeling and the ISH demonstration of VGLUT2 mRNA expression in these cells. In the absence of ultrastructural data, it is presently unclear whether VGLUT2 and the various peptide hormones are localized to the same or to separate vesicular compartments. Anterior pituitary cells are known to possess both secretory granules and synaptic-like microvesicles (42, 43) . In the central nervous system, VGLUT1 and VGLUT2 are contained in small clear vesicles of synaptic terminals (2) (3) (4) 38) . Furthermore, although the analogous organelles, synaptic-like microvesicles contain the VGLUT1 and VGLUT2 isoforms in the pineal gland (19), Hayashi et al. (21) reported that the ␣-cells of the pancreatic Langerhans islets contain VGLUT2 in glucagone-containing secretory granules, and cosecrete stoichiometric amounts of glutamate and glucagone under low glucose conditions. The putative localization of VGLUT2 in adenohypophysial microvesicles appears to gain support from our unpublished observation that gonadotrope and thyrotrope cells are strongly immunoreactive to "SV2", an immunocytochemical marker of synaptic-like microvesicles. However, the presence of VGLUT2 in microvesicles awaits direct ultrastructural confirmation.
The functional significance of VGLUT2 we found in gonadotrope and thyrotrope cells is unclear. In view of recent data showing low-glucose-induced corelease of glutamate with glucagone from endocrine cells of the Langerhans islet (21), glutamate secretion from stimulated adenohypophysial cells is highly possible. Of particular note in the context of the proposed glutamate cosecretion is our observation that the activated thyrotropes of hypothyroid male rats showed not only a decreased TSH immunoreactivity, but their immunostaining for VGLUT2 was also attenuated. The increased secretion rate offers an explanation for the apparent paradox between the increased synthesis and the decreased visibility of both secretory compounds. If glutamate is, indeed, secreted, it likely exerts autocrine and paracrine effects upon the endocrine cells. Corroborating this concept, ionotropic as well as metabotropic glutamate receptors have been identified in adenohypophysial cells (14, 15) . However, it is worth noting that a previous study demonstrated N-methyl-daspartate R1 subunit expression in only relatively low percentages of adenohypophysial cells (Ͻ12% for each cell type) and, unlike we found for VGLUT2, there was no preferential association of N-methyl-d-aspartate R1 with any particular cell type (14) . Furthermore, it seems somewhat paradoxical that group II metabotropic glutamate receptors (mGLUR2/3) have been identified in the somatotrope and lactotrope cells (15) most of which were found in the present study not to contain VGLUT2. One explanation for such a discrepancy may be a putative cross-talk between adenohypophysial cell types (gonadotropes and thyrotropes) secreting glutamate and those having receptors for it. The intimate relationship of lactotrope cells with VGLUT2 expressing gonadotropes, that we observed in the present studies, may support this idea. An example for such a paracrine glutamatergic regulation has been described in the Langerhans islets. Although insulin-secreting ␤-cells are devoid of VGLUTs (21), the stimulation of ␣-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid-type ionotropic glutamate receptors on these cells, FIG. 5 . The effect of thyroid hormone status on adenohypophysial VGLUT2 mRNA expression. Hypothyroidism (induced by a 3-wk treatment of male rats with 0.02% methimazole in the drinking water) caused a significant increase in adenohypophysial VGLUT2 mRNA expression (mean gray value), compared with signal levels found in the untreated euthyroid controls. In contrast, hyperthyroidism induced by daily T 4 injections (10 mg ip., for 10 d) did not affect the VGLUT2 hybridization signals. *, P ϭ 0.0001 vs. hyperthyroid and euthyroid groups by ANOVA followed by Newman-Keuls.
which is likely exerted by the paracrine action of ␣-cellderived glutamate, can enhance the secretion of GABA from synaptic-like microvesicles (21) . We also have to recognize that adenohypophysial cell types not showing VGLUT2 immunoreactivity in the present study may contain low levels of VGLUT2 that are below the detection threshold of our method. In particular, the low percentage (Ͻ8%) of lactotrope, somatotrope, and corticotrope cells that we found to contain VGLUT2 appears to support the hypothesis that these cells may also store glutamate under certain functional conditions. Alternatively, other than the VGLUT2 isoform of VGLUTs may occur in these cells and confer a glutamatergic phenotype. Further studies thus will be needed to address the amino acid content of these cell types.
The up-regulation of adenohypophysial VGLUT2 mRNA levels by estradiol or hypothyroidism may be indicative of increased VGLUT2 protein synthesis when estrogen levels rise or thyroid hormone levels decrease. As gonadotrope cells possess estrogen receptors (44, 45) , and several phenotypes of anterior lobe cells, including thyrotropes and gonadotropes, also possess thyroid hormone receptors (46) , it is possible that nuclear hormone receptors directly regulate VGLUT2 gene expression in these cells. Alternatively, the rise of VGLUT2 mRNA may be secondary to synthetic and secretory changes induced by the altered estrogen and thyroid hormone feedback to the pituitary and/or to the endocrine hypothalamus. The exact mechanisms of these changes and the issue of whether the increased VGLUT2 expression in estrogen-treated and hypothyroid rats is due to an increase in the number of VGLUT2 synthesizing cells, an increase in VGLUT2 mRNA copy number in individual gonadotropes and thyrotropes, or both, will require clarification.
In summary, the present immunocytochemical and ISH studies established the presence of the authentic VGLUT2 molecule in large subsets of gonadotrope and thyrotrope cells and smaller subsets of other cell types in the adenohypophysis. Furthermore, either an estrogen regimen administered to ovariectomized rats, or hypothyroidism induced by methimazole in the drinking water of male rats, could up-regulate adenohypophysial VGLUT2 mRNA levels. Finally, despite the increased VGLUT2 mRNA synthesis in hypothyroid rats, the activated TSH cells of hypothyroid rats exhibited less VGLUT2 immunoreactivity, which may be indicative of an increased rate of glutamate secretion. The physiological significance of endogeneous glutamate stores in adenohypohysial cells will require clarification. . E-H, A large subset of thyrotrope cells (E) also contain VGLUT2 (F) in euthyroid rat, whereas hypothyroidism, induced with methimazole in the drinking water, significantly decreased the ratio of VGLUT2-containing thyrotrope cells. Arrows point to dual-labeled cells in corresponding panels (E and F; G and H). Note the increased size and the attenuated TSH immunostaining of the activated cells (G), in addition to the disappearance of VGLUT2 from many of them. Scale bars, 25 m.
